权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

IEX-1 as a potential biomarker for early detection of myelodysplastic syndromes

IEX-1 作为早期检测骨髓增生异常综合征的潜在生物标志物

基本信息

批准号：
8311631
负责人：
Mei X Wu
金额：
$ 17.24万
依托单位：
MASSACHUSETTS GENERAL HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-09-01 至 2014-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8311631
关键词：
Acute Myelocytic Leukemia Address Aftercare Antioxidants Apoptosis Automobile Driving Biological Assay Biological Markers Bone Marrow Stem Cell CD34 gene Cell Cycle Arrest Cell membrane Cells Chromosomal Loss Cytotoxic Chemotherapy DNA Damage Development Disease Disease Progression Dysmyelopoietic Syndromes Dysplasia Early Diagnosis Elderly Epigenetic Process Equilibrium Exhibits Frequencies Gene Mutation Generations Genes Genomic Instability Genomics Growth Hematopoietic Neoplasms Hematopoietic stem cells Homeostasis Induced Mutation Ineffective Hematopoiesis Investigation Knock-out Knockout Mice Lead Lesion Mitochondria Modification Mus Mutation Myelogenous NADPH Oxidase Oxidative Phosphorylation Patients Play Point Mutation Predisposition Production Radiation Reactive Oxygen Species Recurrence Regulation Respiratory Chain Role Secondary to Site Stem cells Testing Wild Type Mouse base chemotherapy cytopenia inhibitor/antagonist insight mitochondrial dysfunction novel strategies null mutation outcome forecast peripheral blood prevent reconstitution regenerative self-renewal

项目摘要

DESCRIPTION (provided by applicant): The overall objective of this proposal is to determine a potential of IEX-1 (Immediate Early responsive gene X-1) as a biomarker for the early diagnosis of myelodysplastic syndromes (MDS) or its progression to acute myeloid leukemia (AML). MDS is a clonal disorder of hematopoietic stem cells (HSCs) presumably resulting from the accumulation of mutations in genes that control the differentiation, self-renewal, or proliferation of HSCs. An unusual high frequency of genetic alterations in HSCs in MDS patients may be ascribed in part to increased production of reactive oxygen species (ROS) that causes DNA mutations, which could in turn lead to acquisition of additional genomic changes and ROS formation. IEX-1 takes part in regulating a balance between ROS generation and oxidative phosphorylation in mitochondria by targeting the inhibitor of mitochondrial FoF1-ATP synthase (IF1) to degradation. Over-expression of IEX-1 reduced the level of IF1 expression, concomitant with diminished ROS production, protecting cells from mitochondrion-dependent apoptosis. On the contrary, null mutation of IEX-1 stabilized IF1 expression and increased the susceptibility of cells to apoptosis. In accordance with a role of IEX-1 in the survival and differentiation of HSCs, IEX-1 deficient HSCs exhibited a high rate of apoptosis and proliferation but a decrease in their generation. Moreover, several studies recently showed that IEX-1 expression was deregulated in more than half of patients with MDS and the deregulation was correlated with the progression of the disease and the apoptosis level in CD34+ stem cells in the patients. Based on these observations, we hypothesize that deregulation of IEX-1 expression contributes significantly to the development of MDS and its progression to AML. We will test this hypothesis by long term competitive repopulation assays so as to determine whether or how IEX-1 contributes to MDS development via an autonomous or extrinsic fashion. The reconstituted mice will be then treated with anti-oxidant to restore the self-renewal capacity of HSCs. In aim 2, we will expose IEX-1 knockout (KO) mice to radiation or chemotherapy that offers a "second hit", rendering them more susceptible to radiation- or chemotherapy-induced DNA mutations and thus MDS/AML development. An increase in the susceptibility of IEX-1 KO mice to MDS/AML after the treatment will suggest that IEX-1 is one of the "multiple hits" causing the genomic instability in HSCs and can be thus used as a biomarker for the prognosis of myeloid disorders. The study may also provide new insights into the mechanism for the disease development and help to develop novel strategies to prevent it.

描述（由申请人提供）：本提案的总体目标是确定IEX-1（即早反应基因X-1）作为早期诊断骨髓增生异常综合征（MDS）或其进展为急性髓性白血病（AML）的生物标志物的潜力。MDS是造血干细胞（HSC）的克隆性疾病，推测是由控制HSC分化、自我更新或增殖的基因突变积累引起的。MDS患者HSC中异常高频率的遗传改变可能部分归因于导致DNA突变的活性氧（ROS）产生增加，这反过来可能导致获得额外的基因组变化和ROS形成。IEX-1通过靶向降解线粒体FoF 1-ATP合酶（IF 1）抑制剂参与调节线粒体中ROS产生和氧化磷酸化之间的平衡。IEX-1的过表达降低了IF 1的表达水平，同时减少了ROS的产生，保护细胞免受依赖于细胞凋亡的损伤。相反，IEX-1的无效突变稳定了IF 1的表达并增加了细胞对凋亡的易感性。根据IEX-1在HSC存活和分化中的作用，IEX-1缺陷的HSC表现出高的凋亡和增殖率，但其生成减少。此外，最近的一些研究表明，IEX-1的表达失调，在超过一半的MDS患者和失调与疾病的进展和患者的CD 34+干细胞的凋亡水平。基于这些观察，我们假设IEX-1表达的失调显著促进MDS的发展及其向AML的进展。我们将通过长期竞争性再增殖试验来检验这一假设，以确定IEX-1是否或如何通过自主或外在方式促进MDS的发展。然后用抗氧化剂处理重建的小鼠以恢复HSC的自我更新能力。在目标2中，我们将IEX-1敲除（KO）小鼠暴露于放射或化疗，提供“第二次打击”，使它们更容易受到放射或化疗诱导的DNA突变，从而导致MDS/AML的发展。治疗后IEX-1 KO小鼠对MDS/AML的易感性增加将表明IEX-1是导致HSC中基因组不稳定性的“多次命中”之一，因此可用作骨髓疾病预后的生物标志物。该研究还可能为疾病发展机制提供新的见解，并有助于开发新的预防策略。